The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

Pixelligent Technologies

Advised Pixelligent Technologies, a developer and manufacturer of nanocrystal material used in consumer electronic devices, on a significant strategic investment from Henkel Corporation, a publicly traded (FWB: HEN) German multinational chemical and consumer goods company

Juice Plus+

Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction

Marley Spoon business combination with 468 SPAC II

Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

Electro Optic Systems

Advised Electro Optic Systems, an Australian founded and listed aerospace and defence company, on agreeing financing terms with its largest shareholder, Washington H. Soul Pattinson

easyJet plc

Advising and acting as joint sponsor to UK-based easyJet plc, a leading low-cost European airline carrier, on its £1.2bn fully underwritten rights issue & $400m secured RCF

Education Australia’s 40% Stake in IDP Education

Advising ASX-listed IDP Education on the restructure of Education Australia’s 40% ownership stake in the business

Acacia Pharma Group plc

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

Greencore Group plc

Advised Greencore Group plc, a leading UK manufacturer of convenience foods based in Ireland, on its £90mm non pre-emptive equity placing

Rolls-Royce £2bn Fully Underwritten Rights Issue

Advising Rolls-Royce on its Fully Underwritten £2bn Rights Issue, as part of a broader recapitalisation package

Travel & Transport

Advising Corporate Travel Management on its acquisition of US-based travel management company Travel & Transport and the associated A$375mm equity raise

CSM Bakery Solutions

Advised the Ad-Hoc Group of First Lien and Second Lien Lenders on consensual out-of-court amend & extend

WH Smith PLC

Advised WH Smith PLC, one of the UK’s leading retailers, on its £166m non pre-emptive equity placing and new £120mm financing facility

David’s Bridal Inc.

Advised David’s Bridal, a leading bridal gown and special occasion dress retailer, on its out-of-court recapitalization

David's Bridal

Advised the Ad Hoc Group of the company's $481mm term loan with respect to the company's prepackaged Chapter 11 restructuring

The AA plc

Advised the AA plc, the UK’s largest roadside assistance provider, on the refinancing of £825mm of its senior secured facilities

Dairy Crest Group PLC

Advised Dairy Crest, a leading British dairy company, on a non-pre-emptive cash placing, raising proceeds of approximately £70 million

Concordia International Corp.

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

Hirslanden Private Hospital Group

Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt

US rights to Toprol-XL (AstraZeneca)

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

Bionomics Limited

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

Refinancing of syndicated bank debt facilities

Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities

Quindell plc’s Professional Services Division

Advised Slater and Gordon Limited, an ASX-listed international consumer law firm, on the acquisition of Quindell plc’s Professional Services Division, the UK’s leading personal injury law firm operating across the claims value chain, and associated A$890 million equity and A$375 million debt raisings

AA plc

Advised AA plc, the UK’s leading roadside assistance provider, on the refinancing of its high yield bond and PIK instrument

Azelis Group (majority owned by 3i)

Advised 3i on the sale of Azelis Group, a leading pan-European distributor of specialty chemicals with an emerging presence in Asia, to funds advised by Apax partners